TradeOrgs
  • Stocks
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%
RELIANCE₹1,304.00▼ 0.70%TCS₹2,093.50▼ 6.61%HDFCBANK₹801.05▲ 6.29%ICICIBANK₹1,411.40▲ 13.64%INFY₹1,047.20▼ 14.35%HINDUNILVR₹2,201.20▲ 5.29%ITC₹289.95▲ 4.68%SBIN₹1,040.00▲ 7.17%BHARTIARTL₹1,910.40▲ 4.73%KOTAKBANK₹396.75▲ 4.13%LT₹4,026.60▲ 1.86%AXISBANK₹1,342.10▲ 6.92%ASIANPAINT₹2,737.80▲ 2.83%MARUTI₹14,366.00▲ 10.13%AAPL$308.63▼ 2.08%MSFT$390.49▼ 11.52%GOOGL$359.91▼ 0.54%AMZN$242.67▼ 5.40%NVDA$194.83▼ 12.56%META$582.90▼ 2.46%TSLA$393.45▼ 7.15%BRK-B$507.78▲ 7.69%JPM$334.47▲ 11.13%V$362.13▲ 14.12%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← All stocks

🇺🇸AZN

AstraZeneca PLC Ordinary Shares

NYSE
$195.15
▲ $17.70 (+10.0%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 02 Jul 2026
H $212.71L $173.66+6.6%
$212.71$204.9$197.09$189.28$181.47$173.66$195.15
RSI (14)
Intraday · 15-minNeutral-10RSI 73UptrendMACD Bearishfor day-trading context — not advice

Technical signal

Buy+20
RSI (14)62
oversold 30overbought 70
Trend
Sideways
MACD
Bullish
Bollinger
Above upper band
vs 20-day
above
vs 50-day
above
vs 200-day
above
Support
$173.66
Resistance
$196.41
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2025-09-29 → 2026-07-02

Strategy return
+11.7%
Buy & hold
+31.6%
Trades
6
Win rate
67%

$100,000.00 invested would be worth $111,688.69 (+11.7%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About AstraZeneca PLC· Drug Manufacturers - General

source: yahoo

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
96,100
Headquarters

Fundamentals

source: yahoo
Market cap
$302.65B
P/E
29.4
P/B
6.4
EPS
$6.64
Div yield
1.6%
Profit margin
17.2%
ROE
23.5%
Debt / Equity
0.72
Beta
0.23
52-week range
$137.22 – $212.71
52-week low · $137.2277% of rangehigh · $212.71

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive4↑ · 0↓ · 4–
  • Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?▲ Positive
    Motley Fool · 03 Jul 2026
  • [Latest] Global Antidiabetic Drugs Market Size/Share Worth USD 309.84 Billion by 2035 at a 11.62% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)▲ Positive
    GlobeNewswire · 03 Jul 2026
  • AstraZeneca (LSE:AZN) Wins Two EU Cancer Approvals And Starts Abbisko Lung Trial▲ Positive
    Simply Wall St. · 02 Jul 2026
  • Price is above the upper Bollinger Band (stretched to the upside).
  • Educational technical indicators — not investment advice. TradeOrgs does not place trades.

    Cambridge, United Kingdom
    www.astrazeneca.com ↗
    European Stocks Surge, Oil Prices Drop; Defense, Luxury Shares Rally
    ▲ Positive
    MT Newswires · 02 Jul 2026
  • AstraZeneca Collaborating With CSPC Pharma in siRNA Drug Deal Worth Up to $1.77 Billion— Neutral
    MT Newswires · 02 Jul 2026
  • Astrazeneca to Collaborate With Abbisko Therapeutics for Potential Non-Small Cell Lung Cancer Treatment— Neutral
    MT Newswires · 02 Jul 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.